BTK blockers make headway in multiple sclerosis
Elie Dolgin • January 11, 2021
By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.
Continue reading at Nature Biotechnology.
Zebras and giraffes offer one another protection without food competition.
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with fewer side effects.